Berenberg Bank Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price

BioNTech (NASDAQ:BNTX) had its price target lifted by equities researchers at Berenberg Bank from $150.00 to $155.00 in a research note issued on Thursday,MarketScreener reports. The firm presently has a “buy” rating on the stock. Berenberg Bank’s price objective would suggest a potential upside of 60.48% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on BNTX. JPMorgan Chase & Co. decreased their target price on shares of BioNTech from $121.00 to $120.00 and set a “neutral” rating on the stock in a research report on Thursday, October 23rd. Cowen reiterated a “hold” rating on shares of BioNTech in a report on Monday, November 3rd. UBS Group upgraded BioNTech to a “hold” rating in a research note on Thursday, December 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research note on Tuesday, October 14th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $151.00 target price on shares of BioNTech in a report on Wednesday, December 3rd. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $137.75.

BioNTech Stock Performance

Shares of BNTX opened at $96.59 on Thursday. BioNTech has a 1 year low of $81.20 and a 1 year high of $129.27. The company’s 50 day simple moving average is $102.65 and its 200 day simple moving average is $105.09. The company has a market capitalization of $21.75 billion, a price-to-earnings ratio of -36.89 and a beta of 1.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.12.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of $0.75 by ($0.89). BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. The business had revenue of $1.78 billion during the quarter, compared to analyst estimates of $1.21 billion. During the same quarter last year, the firm posted $0.81 earnings per share. The company’s revenue was up 22.0% on a year-over-year basis. On average, sell-side analysts predict that BioNTech will post -3.88 EPS for the current year.

Institutional Investors Weigh In On BioNTech

Hedge funds have recently modified their holdings of the stock. Financial Consulate Inc. purchased a new position in BioNTech in the 3rd quarter worth approximately $36,000. Huntington National Bank lifted its position in shares of BioNTech by 1,266.7% during the third quarter. Huntington National Bank now owns 410 shares of the company’s stock worth $40,000 after purchasing an additional 380 shares in the last quarter. LRI Investments LLC boosted its stake in shares of BioNTech by 234.6% in the second quarter. LRI Investments LLC now owns 445 shares of the company’s stock valued at $47,000 after purchasing an additional 312 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after purchasing an additional 305 shares during the period. Finally, Hantz Financial Services Inc. grew its holdings in BioNTech by 472.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock valued at $61,000 after purchasing an additional 472 shares in the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.